Market share of orphan drugs valued <$6,000 per year in 2017, by therapy class
This statistic depicts the market share of U.S. orphan drugs that cost patients less than $6,000 per year in 2017, by therapy class. In that year, drugs for central nervous system disorders an annual cost of under six thousand dollars per patient accounted for 4.2 percent of the total orphan drug market.